[October 22, 2014]

Acceleron Announces Educational Webcast on Chronic Kidney Disease - Mineral and Bone Disorder

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced it will host and webcast an online educational seminar on chronic kidney disease mineral and bone disorder (CKD-MBD) with Ravi Thadhani, M.D., M.P.H. Acceleron and its collaboration partner, Celgene, are conducting phase 2 clinical trials of sotatercept in patients with end-stage renal disease with mineral and bone disorder.

Dr. Thadhani currently serves as Chief of the Nephrology Division at Massachusetts General Hospital and is also a Professor of Medicine at Harvard Medical School.

Dr. Thadhani will provide an overview of CKD-MBD including clinical manifestations of the disease, current treatment and unmet need. At the end of the presentation, he will be available to answer questions from webcast participants.

To access the live webcast, please visit the "Events & Presentations" page in the Investors & Media section on the Company's website (http://investor.acceleronpharma.com/events.cfm). To ensure a timely connection, it is recommended that users register at least 15 minutes before the scheduled webcast. To participate by teleconference, please dial 877-312-5848 (domestic) or 253-237-1155 (international) and refer to the Acceleron Seminar on CKD. A replay of the webcast will be available on Acceleron's website.

About Chronic Kidney Disease

Chronic Kidney Disease (CKD) is a serious condition characterized by the progressive loss of kidney function and is most often caused by diabetes or high blood pressure. CKD is classified in five stages according to the degree of kidney impairment. End Stage Renal Disease (ESRD), also known as kidney failure, is the most advanced stage of CKD and a life-threatening condition in which patients require a either kidney transplant or dialysis for survival. Anemia, low levels of red blood cells, is a common secondary disorder to Chronic Kidney Disease and worsens with progression of the disease. Disturbance in mineral and bone metabolism, known as Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD), is also a common complication in CKD patients that affects almost all patients who are on dialysis. CKD-MBD can lead to bone abnormalities and/or calcification in soft tissue, especially blood vessels, and is associated with increased morbidity and mortality in CKD patients.

About Acceleron

Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases. The company is a leader in understanding the biology of the Transforming Growth Factor-Beta (TGF-ß) protein superfamily, a large and diverse group of molecules that are key regulators in the growth and repair of tissues throughout the human body, and in targeting these pathways to develop important new medicines. Acceleron has built a highly productive R&D platform that has generated innovative clinical and preclinical protein therapeutic candidates with novel mechanisms of action. These protein therapeutic candidates have the potential to significantly improve clinical outcomes for patients with cancer and rare diseases.

For more information, please visit www.acceleronpharma.com.

[ Back To TMCnet.com's Homepage ]